Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 23, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on the mechanics of a share buyback transaction.
- Shares Purchased: 910,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,478.176 pence per share.
- Treasury Holdings Post-Transaction: 165,624,678 shares.
- Shares in Issue (Excluding Treasury): 5,816,366,159 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 910,000 shares for Treasury. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 910,000 share repurchase based on the stated price of 1,478.176 pence.
- Confirm the updated total share count (5,816,366,159 in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F for revenue and profit metrics.